The Cost of Von Willebrand Disease in Europe: The CVESS Study.
Clin Appl Thromb Hemost
; 28: 10760296221120583, 2022.
Article
em En
| MEDLINE
| ID: mdl-35979588
ABSTRACT
BACKGROUND:
Von Willebrand disease (VWD) is one of the most common inherited bleeding disorders, imposing a substantial health impact and financial burden. The Cost of von Willebrand disease in Europe A Socioeconomic Study (CVESS) characterises the socio-economic cost of VWD across Germany, Spain, Italy, France, and the UK.METHODS:
A retrospective, cross-sectional design captured 12 months of patient disease management, collected from August-December 2018, for 974 patients. This enabled estimation of direct medical, direct non-medical and indirect costs, utilising prevalence estimates to extrapolate to population level.RESULTS:
Total annual direct medical cost (including/excluding von Willebrand factor [VWF]) across all countries was the highest cost (2â 845â 510â 345/444â 446â 023), followed by indirect costs (367â 330â 271) and direct non-medical costs (60â 223â 234). Differences were seen between countries the UK had the highest direct medical costs excluding VWF (159â 791â 064), Italy the highest direct-non medical (26â 564â 496), and Germany the highest indirect cost burden (197â 036â 052). Total direct medical costs per adult patient increased across VWD types with Type 1 having the lowest cost (23â 287) and Type 3 having the highest cost (133â 518).CONCLUSION:
A substantial financial burden arises from the prevalence of VWD for the European healthcare systems considered.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças de von Willebrand
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article